# Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

> **NCT01155791** · PHASE1 · TERMINATED · sponsor: **Sandy Srinivas** · enrollment: 2 (actual)

## Conditions studied

- Urologic Neoplasms
- Prostate Cancer
- Prostate Cancer Metastatic Disease

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Biosyn
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01155791
- **Lead sponsor:** Sandy Srinivas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01155791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01155791, "Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01155791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*